Brokerages Set Phreesia, Inc. (NYSE:PHR) Price Target at $31.33

Phreesia, Inc. (NYSE:PHR) has been given an average recommendation of “Buy” by the twelve brokerages that are currently covering the stock, MarketBeat reports. Twelve equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year is $31.33.

Several equities research analysts have recently commented on the stock. KeyCorp boosted their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Canaccord Genuity Group boosted their price objective on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Robert W. Baird dropped their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and issued a $33.00 price target (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Finally, Truist Financial upped their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th.

Insider Activity

In other Phreesia news, SVP Amy Beth Vanduyn sold 4,720 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $128,903.20. Following the sale, the senior vice president now owns 110,309 shares of the company’s stock, valued at approximately $3,012,538.79. The trade was a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Allison C. Hoffman sold 4,585 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $26.90, for a total transaction of $123,336.50. Following the transaction, the general counsel now owns 154,552 shares in the company, valued at $4,157,448.80. The trade was a 2.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 152,908 shares of company stock worth $4,359,153 over the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. GAMMA Investing LLC increased its holdings in shares of Phreesia by 10,605.7% in the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company’s stock valued at $145,000 after purchasing an additional 5,621 shares during the period. Probity Advisors Inc. purchased a new stake in Phreesia in the fourth quarter valued at approximately $304,000. PharVision Advisers LLC acquired a new position in Phreesia in the 4th quarter worth approximately $302,000. Two Sigma Advisers LP purchased a new position in Phreesia during the 4th quarter worth approximately $302,000. Finally, Silvercrest Asset Management Group LLC lifted its stake in Phreesia by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 394,352 shares of the company’s stock valued at $9,922,000 after acquiring an additional 93,349 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Stock Performance

PHR stock opened at $24.04 on Tuesday. Phreesia has a 1-year low of $17.07 and a 1-year high of $30.53. The business has a 50-day moving average price of $27.10 and a 200 day moving average price of $24.23. The company has a market capitalization of $1.41 billion, a P/E ratio of -16.35 and a beta of 0.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.